The potential of plasma proteomic clocks in detecting AD‐related phenotypes and co‐morbidities possibly constitute confounding factors, compromising the performance of proteomic aging models is illustrated.
Cindy David Sarmento, G. Drouard, T. Saari et al.· Alzheimer's & Dementia· 1 citation
In CSF-confirmed participants, age emerged as the most consistent predictor of plasma biomarker levels, particularly NFL and pTau181, which suggests that plasma biomarkers are influenced primarily by age and genetic background rather than by metabolic factors in this cohort.
Carolin I. Kurz, Marleen Taute, Paulina Tegethoff et al.· Aging Brain· 0 citations
Late-onset depression (LOD) is a common subtype of depression in the elderly, characterized by high disability and recurrence rates, along with poorly understood biological correlates, posing a serious threat to the health of the aging population; moreover, the molecular correlates and diagnostic targets for LOD rema...
Yu-Qi Yan, Hanfang Xu, Tian-Ge Zhang et al.· Journal of Proteome Research· 0 citations
Routine and accessible plasma measures can be leveraged to recover reproducible, biologically distinct progression modules that improve characterization of heterogeneous AD and have practical value for risk stratification, trial enrichment, or treatment monitoring.
R. R. Butler, M. Brown, A. Weber et al.· medRxiv· 1 citation
It is suggested that chronic stress and sleep disturbances exhibit an interactive relationship in their associations with AD pathology, and the need for further research into interactive effects of multiple modifiable risk factors in the development of AD is highlighted.
J. Holleman, I. Kåreholt, Manasa Shanta Näsholm et al.· Journal of Neurology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.